Company overview
ImmuneOncia Therapeutics is a clinical-stage biopharmaceutical company specializing in immuno-oncology, developing novel antibodies and bispecific antibodies targeting PD-L1, CD47, and other pathways for cancers like refractory NK/T-cell lymphoma and hepatocellular carcinoma. Key pipeline candidates include Danburstotug (PD-L1 mAb) advancing to Phase III with Lonza manufacturing support, IMC-002 (anti-CD47), and IOH-001 (CD47/PD-L1 bispecific). The company leverages expertise in drug development and antibody engineering from its headquarters in Yongin-si, South Korea.
Immuneoncia is listed in the NovaPharmaNews Supplier Hub as a Life Science Reagents partner serving United States & Americas. Core focus areas include immuneoncia therapeutics, pd-l1 antibody, cd47 bispecific, immuno-oncology, nk/t-cell lymphoma.
Industry categories: Life Science Reagents. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.immuneoncia.com
- Categories
- Life Science Reagents
- Markets served
- United States & Americas
- Keywords
- immuneoncia therapeutics, pd-l1 antibody, cd47 bispecific, immuno-oncology, nk/t-cell lymphoma
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What are ImmuneOncia's key pipeline products?
- Key candidates include Danburstotug (PD-L1 targeting mAb for refractory NK/T-cell lymphoma entering Phase III), IMC-002 (anti-CD47 for HCC with 50% disease control rate in trials), IOH-001 (CD47/PD-L1 bispecific showing superior tumor suppression), and IMC-201 (selective cancer cell binder).
- What manufacturing capabilities does ImmuneOncia use?
- ImmuneOncia partners with Lonza for end-to-end cGMP manufacturing of Danburstotug at sites in Slough (UK), Basel, and Stein (Switzerland), supporting clinical supply.
- Where is ImmuneOncia located and what is their therapeutic focus?
- Headquartered in Yongin-si, South Korea, ImmuneOncia focuses on immuno-oncology therapies using antibody engineering for solid and hematological cancers.
Related editorial coverage
- Merck’s Harpoon acquisition deepens oncology pipeline ahead of Keytruda risk
- ACRP 2026: Immunology Clinical Research Trends to Watch
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
Explore lab tools and QA/QC resources for R&D teams.
